CL2024002812A1 - Composiciones protésicas de canal iónico que comprenden cristales de anfotéricina b recubiertos de lípidos. - Google Patents
Composiciones protésicas de canal iónico que comprenden cristales de anfotéricina b recubiertos de lípidos.Info
- Publication number
- CL2024002812A1 CL2024002812A1 CL2024002812A CL2024002812A CL2024002812A1 CL 2024002812 A1 CL2024002812 A1 CL 2024002812A1 CL 2024002812 A CL2024002812 A CL 2024002812A CL 2024002812 A CL2024002812 A CL 2024002812A CL 2024002812 A1 CL2024002812 A1 CL 2024002812A1
- Authority
- CL
- Chile
- Prior art keywords
- recubiertos
- protésicas
- lípidos
- iónico
- anfotéricina
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 abstract 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
- 229960003942 amphotericin b Drugs 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263321965P | 2022-03-21 | 2022-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002812A1 true CL2024002812A1 (es) | 2025-01-10 |
Family
ID=88101847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002812A CL2024002812A1 (es) | 2022-03-21 | 2024-09-17 | Composiciones protésicas de canal iónico que comprenden cristales de anfotéricina b recubiertos de lípidos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12419899B2 (enExample) |
| EP (1) | EP4496588A4 (enExample) |
| JP (1) | JP2025510096A (enExample) |
| KR (1) | KR20240164801A (enExample) |
| CN (1) | CN119365218A (enExample) |
| AU (1) | AU2023238751A1 (enExample) |
| CA (1) | CA3250825A1 (enExample) |
| CL (1) | CL2024002812A1 (enExample) |
| CO (1) | CO2024013912A2 (enExample) |
| IL (1) | IL315719A (enExample) |
| MX (1) | MX2024011449A (enExample) |
| WO (1) | WO2023183297A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
| EP4780466A1 (en) * | 2023-09-20 | 2026-07-29 | The Board Of Trustees Of The University Of Illinois | Additive effects for molecular prosthetcs and cftr modulators in cf epithelia |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| CA2194049A1 (en) | 1994-06-28 | 1996-01-11 | Georgi Stankov | Novel clinical uses of polyene macrolides |
| US6323191B1 (en) | 1998-06-19 | 2001-11-27 | Genzyme Corporation | Small molecule chloride transport |
| AUPQ066399A0 (en) | 1999-05-31 | 1999-06-24 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal combination use |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| AU2003304204B2 (en) | 2002-10-29 | 2009-12-24 | Insmed Incorporated | Sustained release of antiinfectives |
| US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| HUP0500846A3 (en) | 2002-12-31 | 2008-10-28 | Nektar Therapeutics | Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
| CA2511555A1 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| EP1631669A2 (en) | 2003-04-09 | 2006-03-08 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
| TWI249408B (en) | 2003-12-10 | 2006-02-21 | Ind Tech Res Inst | New antifungal formulation and manufacturing method thereof |
| US7452524B2 (en) | 2004-01-27 | 2008-11-18 | Gilead Sciences, Inc. | Method for improvement of tolerance for therapeutically effective agents delivered by inhalation |
| WO2005120497A2 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| CN101014322A (zh) | 2004-06-11 | 2007-08-08 | 吉藤德拉·纳提·维玛 | 盐水中富含固醇的添加两性霉素的混合层状脂质体及其制备方法 |
| ES2798263T3 (es) * | 2005-12-08 | 2020-12-10 | Insmed Inc | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| CN104825397A (zh) | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
| HUE031951T2 (en) | 2006-10-10 | 2017-08-28 | Jina Pharmaceuticals Inc | Aqueous systems for lipid-based drug compounds; preparations, processes and their use |
| WO2009006311A2 (en) * | 2007-06-29 | 2009-01-08 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| BRPI1003990B1 (pt) | 2009-10-16 | 2021-09-14 | Lifecare Innovations Pvt. Ltd | Formulação para o tratamento de infecções fúngicas |
| US8507441B2 (en) | 2009-10-22 | 2013-08-13 | University of Pittsburgh—Of the Commonwealth Systems of Higher Education | Use of endostatin peptides for the treatment of fibrosis |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| RU2659729C2 (ru) * | 2012-07-30 | 2018-07-03 | Матинас Биофарма Нанотекнолоджис, Инк. | Кохлеаты, полученные с использованием фосфатидилсерина сои |
| KR102548341B1 (ko) | 2013-10-07 | 2023-06-26 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 개선된 치료 지수를 갖는 암포테리신 b 유도체 |
| JP6796581B2 (ja) | 2014-11-04 | 2020-12-09 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | ミッシングタンパク質の小分子模倣体を用いた生理機能の回復 |
| ES2983639T3 (es) | 2016-04-08 | 2024-10-24 | The Board Of Trustees Of The Univ Illinois | Restauración mediada por moléculas pequeñas de la fisiología de la superficie de las vías respiratorias en epitelios pulmonares humanos de fibrosis quística |
| US10960018B2 (en) | 2016-04-15 | 2021-03-30 | The Uab Research Foundation | Methods and compounds for stimulating read-through of premature termination codons |
| PT3694526T (pt) * | 2017-10-11 | 2025-01-20 | Univ Illinois | Resgate independente do genótipo da fibrose quística com canais de bicarbonato de moléculas pequenas |
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
-
2023
- 2023-03-21 IL IL315719A patent/IL315719A/en unknown
- 2023-03-21 JP JP2024556375A patent/JP2025510096A/ja active Pending
- 2023-03-21 WO PCT/US2023/015762 patent/WO2023183297A1/en not_active Ceased
- 2023-03-21 KR KR1020247034896A patent/KR20240164801A/ko active Pending
- 2023-03-21 AU AU2023238751A patent/AU2023238751A1/en active Pending
- 2023-03-21 EP EP23775542.6A patent/EP4496588A4/en active Pending
- 2023-03-21 CA CA3250825A patent/CA3250825A1/en active Pending
- 2023-03-21 CN CN202380041480.3A patent/CN119365218A/zh active Pending
-
2024
- 2024-09-17 CL CL2024002812A patent/CL2024002812A1/es unknown
- 2024-09-18 MX MX2024011449A patent/MX2024011449A/es unknown
- 2024-09-20 US US18/891,739 patent/US12419899B2/en active Active
- 2024-10-16 CO CONC2024/0013912A patent/CO2024013912A2/es unknown
-
2025
- 2025-09-04 US US19/318,694 patent/US20260199383A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4496588A4 (en) | 2026-04-22 |
| EP4496588A1 (en) | 2025-01-29 |
| US20260199383A1 (en) | 2026-07-16 |
| CN119365218A (zh) | 2025-01-24 |
| KR20240164801A (ko) | 2024-11-20 |
| CA3250825A1 (en) | 2023-09-28 |
| JP2025510096A (ja) | 2025-04-14 |
| MX2024011449A (es) | 2024-12-06 |
| AU2023238751A1 (en) | 2024-10-31 |
| WO2023183297A1 (en) | 2023-09-28 |
| US12419899B2 (en) | 2025-09-23 |
| US20250009776A1 (en) | 2025-01-09 |
| CO2024013912A2 (es) | 2025-01-13 |
| IL315719A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024011449A (es) | Composiciones protésicas de canales iónicos que comprenden cristales de anfotericina b recubiertos con lípidos | |
| US9931209B2 (en) | Orthopedic implants | |
| Daniel et al. | Rhinoplasty: nasal anatomy | |
| Friedman et al. | Intranasal and transantral ethmoidectomy: a 20‐year experience | |
| DK0833643T3 (da) | Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme | |
| DE60121012D1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
| BRPI0312128B8 (pt) | formulação farmacêutica compreendendo azelastina e éster de fluticasona | |
| HRP20040352B1 (en) | Use of flibanserin in the treatment of sexual disorders | |
| US20220296825A1 (en) | Exhalation delivery system for and method of treating sinus disease | |
| NZ510887A (en) | Formulations of fexofenadine for ocular and nasal delivery | |
| CA2240717A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| CN105025904A (zh) | 用顺铂脂质复合物预防癌症的肺部复发 | |
| WO2003079992A3 (en) | Pulmonary delivery for levodopa | |
| BG104797A (en) | Use of dexmedetomi dine for sedative effect in patients in an intensive care unit | |
| PT1069902E (pt) | Utilizacao de fosfolipidos na producao de um medicamento para a prevencao de adesoes | |
| CA2886499A1 (en) | Methods and apparatuses for increasing mucociliary clearance | |
| SA03240393B1 (ar) | مضادات مستقبل 5-HT IB/Id لعلاج الصداع headache الناتج عن تناول مضاد مستقبل إندوثيلين endothelin receptor antagonist | |
| BRMU8402975U (pt) | aumentador de corpo capaz de ser implantado através de um pedìculo para reconstrução de corpo vertebral | |
| WO2001089494A8 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| ATE310509T1 (de) | Methode zur behandlung eines analgesiebedürftigen patienten | |
| GB2368795A (en) | Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) | |
| BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
| WO2004023979A3 (en) | Mucus formulation for mucosal surfaces and uses thereof | |
| ES2146580T3 (es) | Agente tensioactivo sintetico para los pulmones. | |
| Jain et al. | Oculocardiac reflex in an anophthalmic eye |